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Reﬂective random indexingPharmacovigilance involves continually monitoring drug safety after drugs are put to market. To aid this
process; algorithms for the identiﬁcation of strongly correlated drug/adverse drug reaction (ADR) pairs
from data sources such as adverse event reporting systems or Electronic Health Records have been devel-
oped. These methods are generally statistical in nature, and do not draw upon the large volumes of
knowledge embedded in the biomedical literature. In this paper, we investigate the ability of scalable Lit-
erature Based Discovery (LBD) methods to identify side effects of pharmaceutical agents. The advantage
of LBD methods is that they can provide evidence from the literature to support the plausibility of a drug/
ADR association, thereby assisting human review to validate the signal, which is an essential component
of pharmacovigilance. To do so, we draw upon vast repositories of knowledge that has been extracted
from the biomedical literature by two Natural Language Processing tools, MetaMap and SemRep. We
evaluate two LBD methods that scale comfortably to the volume of knowledge available in these repos-
itories. Speciﬁcally, we evaluate Reﬂective Random Indexing (RRI), a model based on concept-level
co-occurrence, and Predication-based Semantic Indexing (PSI), a model that encodes the nature of the
relationship between concepts to support reasoning analogically about drug-effect relationships. An eval-
uation set was constructed from the Side Effect Resource 2 (SIDER2), which contains known drug/ADR
relations, and models were evaluated for their ability to ‘‘rediscover’’ these relations. In this paper, we
demonstrate that both RRI and PSI can recover known drug-adverse event associations. However, PSI per-
formed better overall, and has the additional advantage of being able to recover the literature underlying
the reasoning pathways it used to make its predictions.
 2014 Elsevier Inc. All rights reserved.1. Introduction
An adverse drug reaction (ADR) is an ‘‘appreciably harmful or
unpleasant reaction, resulting from an intervention related to the
use of a medical product’’ [1]. ADRs were reported to be between
the fourth and sixth leading cause of death in the United States
in 1994 [2], accounting for 3–7% of medical hospital admissions
[3,4] and a substantial number of health care visits [5]. They have
a considerable negative impact on health and the healthcare sys-
tem, despite the fact that extensive pre-marketing clinical trials
are designed to test drug safety and efﬁcacy. For example Phase
III clinical trials have been estimated to cost 86.3 million U.S. dol-
lars and last 30.5 months on average [6]. Nonetheless, rare ADRs
may not be detected due to the limited duration and sample size
of such trials, and others may occur on account of idiosyncraticcharacteristics of individuals excluded from the evaluated sample.
The continued monitoring for ADRs after drugs are released into
the market, called pharmacovigilance (PV), is therefore an impor-
tant tool to monitor and improve drug safety.
Over the last decade, drug safety data obtained from spontane-
ous reporting systems (SRSs) have been analyzed using quantita-
tive data mining procedures to retrieve strongly associated drug/
ADR pairs [7–9]. These highlighted associations are subsequently
reviewed and scrutinized by domain experts. Unfortunately,
research suggests data collected by SRS are limited by long time
latency, incorrect or incomplete clinical information, underreport-
ing and reporting bias [10,11]. Consequently, clinicians and
researchers have also utilized existing healthcare data sources such
as Electronic Health Records (EHRs) to attempt to identify previ-
ously unreported ADRs [12–15]. However, these data are inher-
ently noisy as drugs and potential side effects may co-occur in
the EHR for many reasons. In addition, the EHR often contains
free-text data, and the accuracy of Natural Language Processing
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identify potentially hazardous drug/ADR associations. Conse-
quently, the development of computational approaches to more
accurately detect potential side effects is currently an active area
of research [16–20]. These approaches have predominantly
focused on improving signal detection using statistical methods,
machine learning (ML) or some combination thereof.
In this paper, we develop an approach that is conceptually dif-
ferent than, and complementary to, such efforts. Methods of liter-
ature-based discovery (LBD) are used to detect potential drug/
ADR associations and to retrieve literature that supports their
plausibility. The paper proceeds as follows. First we discuss the
signiﬁcance and challenges of pharmacovigilance, and how LBD
methods might address these. We then provide relevant back-
ground on recent developments in LBD; and introduce the NLP
tools that were used to extract knowledge from the literature
for our experiments. We then discuss these experiments, in which
we attempt to identify known ADRs using knowledge from the
biomedical literature, and discuss their implications for pharma-
covigilance practice.2. Background
2.1. Pharmacovigilance: post-marketing drug surveillance
Vioxx (Rofecoxib) was withdrawn voluntarily from market by
Merck in 2004, after it was found that the use of this agent
increased the risk of myocardial infarction [21]. Avandia (Rosiglit-
azone) was suspended from the European market in 2010 [22–24]
on account of an increased risk of cardiovascular complications.
These high-proﬁle examples illustrate that PV is an important sup-
plement to existing drug safety proﬁles because clinical drug trials
cannot be large or long enough to identify all problems related to a
new drug [7]. Additionally, subjects are pre-selected by eligibility
criteria and therefore may not fully represent the patient popula-
tion after the drugs are put to market [25]. Consequently, it is
highly unlikely that instances of all possible ADRs will be detected
during pre-marketing clinical trials.
The fact that more than 75 drug products were removed from
the market due to safety problems between 1964 and 2002 further
emphasizes the importance of post-marketing drug monitoring,
known as PV – ‘‘the science and activities relating to the detection,
assessment, understanding and prevention of adverse effects or
any other drug-related problem after drugs are on market’’ [26].
PV is designed to detect any rare or long-term adverse effects over
a very large population and a long period of time. To advance this
aim, health departments and organizations (such as the World
Health Organization (WHO), U.S. Food and Drug Administration
(FDA), and European Medicines Agency (EMA)) encourage physi-
cians, other health care professionals, and patients to report volun-
tarily about any observed ADRs. In addition to voluntarily
reporting, pharmaceutical companies are required to report serious
adverse events [27]. These bodies have Spontaneous Reporting
Systems (SRSs) to enable the efﬁcient submission of reports
electronically [28,29].
In general, the PV process proceeds as follows [30,31]:
(1) Reported drug-related problems are collected in SRSs
nationally or internationally.
(2) Quantitative data mining procedures are used to analyze
these data and retrieve relatively strongly correlated drug/
ADR pairs (drug/ADR associations).
(3) These highlighted associations are then reviewed and evalu-
ated by domain experts making up an expert clinical review
panel.(4) Associations considered to be of clinical interest are then
annotated as signals.
Speciﬁcally, signal is deﬁned as ‘‘reported information on a pos-
sible causal relationship between an adverse event and a drug, the
relationship being unknown or incompletely documented previ-
ously’’ [32]. Overall, the PV process includes two components – a
statistical component (quantitative signal detection, steps (1) and
(2)) and a qualitative component (expert clinical review, steps
(3) and (4)) [31].
Through PV, international and national health institutions
gather large amounts of data from SRS for further analysis. In addi-
tion, researchers have leveraged the opportunity provided by
broader availability of EHRs by utilizing EHR data for signal detec-
tion [12,33]. These authors argue that EHR data can compensate for
some of the deﬁciencies of SRS, such as under-reporting, misclassi-
ﬁcation, a long lag time between observation and reporting, report-
ing bias and the provision of incomplete clinical information [7,8].
Regardless of source, statistical algorithms are applied to both SRS
[34–39] and EHRs [12] to measure the strength of observed drug-
event associations.
It has been argued, though, that causality assessment is lacking
in pharmacovigilance practice [25]. While expert clinical review is
designed to verify potential ADRs, it is a human-intensive and
time-consuming process. The available human resources are
inadequate to review the large amount of noisy signal detected
in SRS and EHR data, creating a bottleneck in the PV process. More
research is needed to develop methods to automate, or assist with,
the knowledge-intensive task of expert clinical review.
2.2. Assessment of causality
To address the issue of causality assessment, general principles
exist that can be applied to evaluate the causality of potential ADRs
[40]. The theoretical basis for these principles was proposed by Sir
Austin Bradford-Hill in 1965 [41]. Bradford-Hill, an English epide-
miologist and statistician, was the ﬁrst to demonstrate that ciga-
rette smoking contributes toward lung cancer using what are
now referred to as the ‘‘Bradford-Hill criteria’’ [42]. The Bradford-
Hill criteria provide viewpoints from which to evaluate evidence
indicative of causality. These criteria are named ‘strength’, ‘consis-
tency’, ‘speciﬁcity’, ‘temporality’, ‘biological gradient’ (referring to
dose–response relationships), ‘plausibility’, ‘coherence’, ‘experi-
mental evidence’, and ‘analogy’ [41,43,44]. Since then, the criteria
have been widely used in epidemiology and may be applied to
assess the causality of drug/ADR relationships [25,40,45]. Three
of these criteria seem particularly pertinent to the development
of pharmacovigilance methods:
 The strength criterion reﬂects that strong associations are
more likely to be causal than weak associations [40]. Quan-
titative statistical data mining methods evaluate adverse
drug reaction signal from the strength of association point
of view.
 The plausibility criterion relates to evidence about mecha-
nisms that may be involved to support a causal
relationship.
 The coherence criterion relates to the consistency of the
hypothesis in question with contemporary medical
knowledge.
Review by domain experts is required to evaluate a signal from
the above points of view using their knowledge and judgment to
ﬁnd a signal with clinical signiﬁcance. However, on account of
the human-intensive nature of this task, automated assistance is
desirable. In this study, we attempt to partially automate this
N. Shang et al. / Journal of Biomedical Informatics 52 (2014) 293–310 295aspect of the signal evaluation process. We do so using methods
that leverage knowledge extracted from the biomedical literature
as a means to assess the plausibility of an observed association.
As one of these methods involves automated analogical reasoning,
it is interesting to note that Bradford-Hill also permitted reasoning
by analogy as an indicator of causality.
2.3. Literature-based discovery
Processing published biomedical literature to uncover implicit
relationships among entities is referred to as literature-based dis-
covery (LBD) [46–49]. LBD involves ﬁnding new knowledge by ana-
lyzing the literature, rather than through scientiﬁc experimentation.
This is accomplished by identifying hidden connections between
entities described in the published literature [46,50]. The origins
of LBD may be traced to the serendipitous discovery that ﬁsh oils
can be therapeutically useful in the treatment of Raynaud’s syn-
drome (poor circulation in the peripheries) by information scientist
Don Swanson [46,50]. Weeber describes two types of LBD [48].
One type, referred to as ‘‘open LBD’’, starts from a known term
or concept (generally called A, although also referred to as C in
Swanson’s early work) and tries to ﬁnd an interesting hypothesis
in the form of a previously unrecognized connection to some other
term. If an article argues that A is associated with B and a second
article mentions that B is associated with C;A may treat C. For
example dietary ﬁsh oil ðAÞ affects platelet aggregation, blood vis-
cosity and vascular reactivity ðBÞ, and these biological factors ðBÞ
play a role in Raynaud’s syndrome ðCÞ [50]. Consequently, it is rea-
sonable to hypothesize that A treats C. The open LBD process pro-
ceeds from the source term A to an unknown target term C and
culminates in the generation of a new hypothesis.
The second type of LBD is referred to as ‘‘closed LBD’’. In a closed
LBD process the goal is to evaluate an existing hypothesis. Closed
LBD starts with known terms A and C, with the goal to identify
intermediate terms B that provide the bridge between A and C
[48]. For example, in 1988 Swanson found intermediate concepts
to explain a hypothetical relationship between migraine and mag-
nesium [51]. Smalheiser and Swanson used closed LBD to propose
an explanation for epidemiologic evidence that estrogen might
protect against Alzheimer’s disease [52].
LBD methodologies generally utilize statistical information
derived from the frequency with which terms, or discrete concepts
extracted from the literature using automated tools (e.g. MetaMap)
or assigned to it by human annotators [53], co-occur [54,55]. This
has been referred to as the co-occurrence model [56]. These co-
occurrence statistics are interpreted by correlation mining and
ranking algorithms [55,57].
A limitation of these methods is that they generally do not con-
sider the nature of the relationship between the terms or concepts
concerned. To address this limitation, Hristovski et al. [54] propose
using semantic relations to eliminate spurious relationships intro-
duced by frequently co-occurring concepts that are not meaning-
fully related. In their initial work, the semantic relations
concerned were extracted from the literature by two Natural Lan-
guage Processing (NLP) systems: SemRep [58] and (speciﬁcally to
extract phenotypic information) BioMedLEE [59]. Their approach
involved the speciﬁcation of ‘‘discovery patterns’’, patterns of rela-
tionships between concepts that may indicate an implicit thera-
peutic relationship [60]. These conditions can be speciﬁed as sets
of semantic predicates. For example, Ahlers et al. [61] deﬁned the
May_Disrupt pattern as follows:
Substance X hinhibitsi Substance Y
Substance Y hcausesjpredisposesjassociated withi Pathology Z
Substance X hmay disrupti Pathology ZVariants of this approach have been applied to generate or sup-
port the hypotheses that ﬁsh oil treats Raynaud’s disease [54],
insulin treats Huntington disease [54], and antipsychotic agents
prevent cancer [61]. Recently, this approach was also adapted to
provide evidence to support the plausibility of an observed drug/
ADR association [62,63], providing proof-of-concept that LBD
methods can be applied within the problem domain of pharmaco-
vigilance. Regardless of the application domain, knowledge used to
populate discovery patterns is extracted from the biomedical liter-
ature using NLP.
2.4. MetaMap and SemRep
MetaMap is a widely-used NLP tool that identiﬁes concepts
from the Uniﬁed Medical Language System (UMLS) in biomedical
text [64,65]. SemRep [58,66] is a rule-based Natural Language Pro-
cessing tool [67] that draws on concepts extracted by MetaMap
and medical domain knowledge in the UMLS to extract semantic
predications [58]. Its input consists of sentences from the litera-
ture; its output is a series of semantic predications identiﬁed in
the respective text. A semantic predication is a subject-predicate-
object triple in which the subject and object are UMLS concepts
and the predicate is a semantic relationship. For example, metfor-
min (UMLS Concept C0025598) TREATS diabetes mellitus
(C0011849) is a semantic predication extracted from the phrase
‘‘Treatment of diabetes mellitus with metformin’’. Evaluations of
SemRep reveal a precision between 0.73 and 0.81, and a recall of
0.55 on the biomedical literature [67–69]. Semantic predications
beneﬁt the LBD process in several respects. The additional informa-
tion provided by semantic predications makes the LBD results eas-
ier to interpret. In addition, it has been noted that a large number
of uninformative co-occurrences must be manually reviewed when
LBD is based on lexical statistics alone [70]. In contrast, semantic
predications provide the means to isolate relationships between
concepts that are logically connected in a meaningful way.
2.5. Semantic vectors for scalability
Regardless of whether co-occurrence relations or discovery pat-
terns are used, LBD systems must explore large numbers of possi-
ble reasoning pathways to identify explanatory hypotheses
(for closed discovery) or previously unrecognized relationships
(for open discovery). Consequently, the process of LBD can be com-
putationally expensive, and thus faces scalability issues in the con-
text of the rapid growth of the biomedical literature. In contrast,
the ﬁeld of distributional semantics has produced corpus-derived
statistical models that can measure the relatedness between two
concepts by comparing vector representations of these concepts,
called semantic vectors, that are derived from the contexts they
have occurred in [71], without the need to explicitly explore co-
occurring concepts once the initial model has been generated. Con-
sequently, several authors have explored the use of distributional
models for LBD [72–74]. These geometrically motivated models
of distributional semantics represent terms or concepts as high-
dimensional vectors derived from the contexts in which they have
occurred. Relatedness between a pair of terms or concepts is then
estimated from the similarity between the vectors [74].
Random indexing (RI), a relatively recent development, further
improves the scalability of distributional methods by avoiding
computationally intensive approaches to dimensional reduction
of the original term-by-context matrix [75,76]. The algorithm’s
computational complexity scales linearly with increasing size of
the input data. It can be incrementally updated as new documents
are added without retraining the whole dataset; thus it is applica-
ble to large corpora such as MEDLINE.
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two variants of RI that have been applied to LBD in our previous
work can identify known side effects of pharmaceutical agents.
To implement a co-occurrence based approach, we use Reﬂective
Random Indexing (RRI) [74]. To implement a discovery pattern
based approach, we use Predication-based Semantic Indexing
(PSI) [77]. On account of their scalability, these models permit
inference on a scale that would be prohibitively time-consuming
if explicit exploration of all possible reasoning pathways were
attempted. This is accomplished through a mechanism known as
‘‘indirect inference’’ [78], which enables distributional models to
ﬁnd meaningful connections between terms that do not co-occur
with one another directly, without the need to explore intervening
terms explicitly.
3. Materials and methods
3.1. Materials
In this study, MetaMapped Medline Baseline (MMB) and
Semantic MEDLINE Database (SemMedDB) were used to represent
knowledge from the biomedical literature. Side Effect Resource 2
(SIDER2) was used as data set for drug/ADR associations. The
Semantic Vectors package was used to build concept-based (RRI)
and predication-based (PSI) semantic space models [74,77].
3.1.1. MMB and SemMedDB
We used the 2012 MMB as a repository for concept-based
modeling. The MMB contains 20,494,848 articles included in
Medline up to November, 2011 and contains 399,701 distinct
concepts. We used the SemMedDB V2.2 (semmedVER22) for this
experiment, which was processed by SemRep version 1.5. This
was the current version when our experiments started. Sem-
MedDB contains 22,252,812 citations included in Medline up to
March 31, 2013 and contains 63,795,467 predications. There are
58 distinct predicates and 257,350 distinct concepts in Sem-
MedDB. There are also negated predications in the SemMedDB
repository (e.g. anticoagulant_therapy NEG_TREATS (does not
TREAT) phlebitis). However, the number of negative predications
is relatively small (1.2% of total predications), so we did not
include these predications in the PSI model.3.1.2. SIDER2
SIDER2 is a publicly available database containing information
on marketed medicines and their known adverse reactions [79].
SIDER2 was used to construct a dataset for our experiment and
as a reference standard to conﬁrm whether a predicted side effect
is a true adverse reaction. We normalized SIDER2 terms by map-
ping drug and side effects terms to UMLS CUI with UMLS Terminol-
ogy Services (UTS) API 2.0 [80] and then subsequently searching
these UMLS CUIs in SemMedDB and MMB to retrieve the mapped
UMLS concepts which are represented in SemMedDB and MMB.
SIDER2 contains 996 drugs, 4192 side effects, and 99,423 drug/
ADR pairs. Only those side effects and drugs that were represented
in both the RRI and the PSI spaces were retained, so our reference
set contains 959 drugs, 3436 side effects, and 90,787 drug/ADR
pairs. Each vector model’s search space was composed of vectors
representing the SIDER2 side effects. For the PSI model, SIDER2
drug/ADR pairs were also used as training data to infer predicate
reasoning pathways.
3.1.3. MEDication–Indication (MEDI)
As we would anticipate connections in the literature between
medications and diseases they treat, we evaluated the utility of
another knowledge resource, MEDI [81], as a means to eliminatedrug indications from consideration as potential side effects. MEDI
is a medication indication resource that was extracted from a set of
commonly used medication resources, including RxNorm, Med-
linePlus, SIDER2, and Wikipedia [81]. MEDI drugs are represented
by RxNorm codes, and indications are represented by ICD-9 codes.
MEDI contains 3112 medications and 63,343 medication–indica-
tion pairs. Additionally, the MEDI high-precision subset (MEDI-
HPS) was created by only including indications that are retrieved
from RxNorm or at least two of the three other resources. MEDI-
HPS contains 2136 medications and 13,304 medication–indication
pairs. The estimated precision of MEDI-HPS is about 92% [81].
In our experiments, MEDI was used to eliminate drugs’ indica-
tions from the side effects search space. To do so, we ﬁrst needed
to normalize all terms representing drugs (RxCUI) and indications
(ICD-9 codes) in MEDI to UMLS concepts, and then ﬁltered each
drug’s indications from this drug’s search space. In many cases,
there exist hierarchical relationships between concepts. For exam-
ple, C0264702 Acute myocardial infarction of apical–lateral wall is
a child node of C0155626 Acute myocardial infarction. So in our
experiment, we extended the MEDI list by aggregating the related
concepts by different hierarchical relations. We tested these vari-
ous extensions of the MEDI list as different MEDI interventions.
3.2. Methods
3.2.1. RRI
Reﬂective Random Indexing (RRI) [74] is a variant of RI adapted
to enable the recognition of meaningful indirect associations. The
variant of RRI we used for our experiments allows for the estima-
tion of semantic relatedness between UMLS concepts, and pro-
ceeds as follows.
First, all terms in the text corpus are assigned unique vector
representations, known as elemental vectors. We will refer to the
elemental vector for concept C as EðCÞ for remainder of this man-
uscript. In accordance with the RI paradigm [82], elemental vectors
are generated stochastically. In this way, RI creates unique ﬁnger-
prints for all terms in the text corpus. The vector components can
be binary, ternary, real, or complex values [82,83]. In our experi-
ments, we use 32,000 dimensional binary vectors constructed in
accordance with the Binary Spatter Code (BSC) [84], one of a family
of representational approaches known as Vector Symbolic Archi-
tectures (VSAs) [84–87]. This dimensionality was selected based
on the results of simulation experiments in previous research
[88], which suggest that at this dimensionality around 2000 unique
elemental vectors can be superposed with low probability of the
superposed product being closer to some other elemental vector
in the space than its component vectors. However, we did not
attempt to optimize this parameter, and would anticipate some
improvement in accuracy in exchange for the additional computa-
tional work required to perform these experiments at higher
dimensionalities. In the BSC, elemental vectors are constructed
by distributing an equal number of 1’s and 0’s at random across
the dimensions of the vector concerned. Consequently, elemental
vectors have a high probability of being orthogonal or close-to-
orthogonal to each other, with orthogonality deﬁned as a Ham-
ming Distance (HD) of half the dimensionality of the vectors con-
cerned [75,84,86].
The next step is to generate vector representations of docu-
ments, by superposing the elemental vectors of the terms con-
tained in these documents. With binary vectors, superposition is
accomplished by keeping track of the number of 1’s and 0’s that
have been added in each dimension, and assigning the value in this
dimension using the majority rule, with ties split at random. We
will refer to this operation by using the ‘‘+’’ symbol, with ‘‘+=’’ indi-
cating a superposition that includes the vector on the left of the
operator also (so DOC Dð Þþ ¼ E Cð Þ is equivalent to DOCðDÞ =
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experiments, this superposition is weighted using the Log-Entropy
weighting procedure. The local term weight for term i in document
j (lij) is derived from the frequency of a term in a document. The
global weight for term i (gi) describes the frequency of the term
within the entire text corpus. They are computed with Eq. (1):
LogEntropyðterm i; doc jÞ ¼ lij  gi
lij ¼ logðterm i;document jÞ ¼ logð1þ tfijÞ
gi ¼ Entropyðterm iÞ ¼ 1
X
j





tfij ¼ number of occurrences of term i in document j
gfi ¼ global frequency for term i; i:e: the total number
of occurrences of term i in the whole text corpus
n ¼ total number of documents in text corpus
ð1Þ
This weighting scheme reduces the inﬂuence of high frequency
terms that may be uninformative, and tempers the inﬂuence of
terms that recur frequently within a single document [89]. Once
document vectors have been generated (Eq. (2)), it is possible to
generate vector representations of concepts (in our case, or terms
in the general case), known as semantic vectors. We will refer to
the semantic vector for concept C as S(C). Semantic vectors are con-
structed by superposing vector representations of the documents a
concept occurs in.
S docð Þþ ¼ E termð Þ  local weight  global weight
¼ E termð Þ  lij  gi ð2Þ
Superposition of binary vectors requires maintaining a ‘‘voting
record’’ that keeps track of the number of 1’s and 0’s added in each
dimension. When local and global weighting metrics are utilized,
the ‘‘votes’’ may not be integer values. So, for example, if the vector
1010 were added with a weight of 0.5, a straightforward imple-
mentation of the voting record would add 0.5 to the dimensions
of the voting record corresponding to the 1’s, and subtract 0.5 from
the dimensions corresponding to the 0’s. Normalization involves
tallying these votes. After training is complete, those dimensions
of the voting record with positive values would be assigned 1,
those with negative values would be assigned 0, and those with
a zero value would be assigned either 1 or 0 at random. In practice,
however, it is computationally inconvenient to maintain and
update 32,000 real values to serve as a voting record for each
semantic vector. Consequently, the Semantic Vectors package
employs a binary matrix approximation of the voting record, which
sacriﬁces some ﬂoating-point precision in exchange for computa-
tional efﬁciency. These implementation details are provided in
[83].
These operations are expressed concisely in the pseudo code in
Fig. 1, adapted from [74]. A schematic representation for RRI
is shown in Fig. 2. We used Semantic Vectors Version 3.7 to
build RRI vectors. Once semantic vectors were constructed, the
relatedness between drugs and ADRs was estimated as
1 2nHammingDistanceðx; yÞ
 
. Therefore, a ranked list of ADRs
for each drug was provided.
3.2.2. PSI
3.2.2.1. Operations in PSI. The PSI model provides the means to
implement discovery patterns for LBD using distributional seman-
tics [77,90]. This is accomplished by representing concepts and
relationships extracted by SemRep as high-dimensional vectors
using an adaption of RI. In previous work, PSI has been applied to
discover therapeutic relationships [77] using a two-stage process
of discovery by analogy: ﬁrst a geometric operator is used to infer
discovery patterns from known treatments, then the identiﬁeddiscovery patterns are used to infer previously unseen therapeutic
relationships.
In addition to the superposition operation described previously,
the PSImodel utilizes a binding operation. Binding () is a composi-
tional operation that is provided by VSAs, such as the BSC [86,87].
Binding two elemental vectors generates a third vector, which is
dissimilar from these two component vectors. The binding opera-
tion is reversible (release ).Withbinary vectors, pairwise exclusive
OR (XOR) is used to accomplish both binding () and release ( ).
3.2.2.2. PSI training process. The training process for generating
semantic vectors proceeds as follows:
(1) Generate elemental vectors for all concepts and relations
occurring in semantic predications.
(2) Generate a semantic vector for each concept, initially empty.
(3) For each predication (concept–predicate–concept), bind the
elemental vector of one concept and the elemental vector
of the predicate, and add this bound product to the semantic
vector for the other concept.
During step (3), a statistical weighting scheme is applied. For
the predication C1 P C2, the semantic vector S C2ð Þ is generated as
shown in Eq. (3).
S C2ð Þþ ¼ E Pð Þ  E C1ð Þ  Pf  idfP þ idfC1
  ð3Þ
The global weight Pf is derived from the number of times that
the predication occurs in the SemMedDB. The local weight idf
(inverse document frequency of the concept c or the predicate p)
reﬂects the occurrence of the concept across all documents. They
are computed as shown in Eq. (4).
Pf ¼ log 1þ occurrences of predication C1 P C2ð Þ
idfc=p ¼ log number of total predicationsnumber of predications containing c=p
  ð4Þ
The pseudo code for PSI is displayed in Fig. 3.
All concepts and relations were assigned a binary elemental
vector of 32,000 bits in length. The semantic vector of each concept
was generated by superposing bound products related to this con-
cept, where the bound products were produced by binding the ele-
mental vectors for the other concept and predicate elemental
vectors in each predication this concept occurs in. The search space
of SIDER2 side effects contains 3436 ADRs.
3.2.2.3. Inferring discovery patterns. After training the semantic vec-
tors, the PSI model can be used to infer discovery patterns by
‘‘releasing’’ the semantic vector of a drug using the semantic vector
of its ADR.
The bound product of the drug’s semantic vector and discovery
patterns’ vectors can be subsequently used as a query vector to
search the vector space of side effects. In our procedure, discovery
patterns were inferred from all known drug/ADR associations. For
each drug, the ﬁve discovery patterns that were most frequently
inferred from all other drugs and their ADRs were retained.
The pathways connecting drugs to side effects may not be
restricted to one middle term (and two predicates). In previous
experiments predicting therapeutic relationships, performance
was improved by including pathways of three predicates and two
middle terms [90]. This is accomplished by generating a second-
degree semantic vector for a concept, S2 conceptð Þ, by adding
together the (ﬁrst-degree) semantic vectors of all concepts con-
nected to it by a predicate of interest. In our experiments, the
two most popular predicates from inferred double-predicate
reasoning pathways – INTERACTS_WITH and COMPARED_WITH –
were used to build second-degree semantic vectors S2. This vector
Fig. 1. The pseudo code for RRI model training process.
298 N. Shang et al. / Journal of Biomedical Informatics 52 (2014) 293–310is then used as an alternative starting point for the inference pro-
cedure. From this point, the ﬁve most frequently inferred double-
predicate reasoning pathways using the second order semantic
vector of all other drugs and the (ﬁrst order) semantic vectors of
their ADRs were retained. As these inferred pathways connect to
drugs through either INTERACTS_WITH or COMPARED_WITH, they
are referred to as triple-predicate pathways.3.2.2.4. Applying discovery patterns to ﬁnd possible ADRs (Step 5 in
Fig. 4). To combine query vectors for frequently inferred reasoning
pathways into one search expression, we use a disjunction opera-
tion that originates in the quantum logic of Birkhoff and von Neu-
mann, and was ﬁrst applied to information retrieval by Widdows
and Peters [91,92]. We deﬁne the disjunction of these ﬁve query
vectors as a query subspace derived from them using a binary vec-
tor approximation [93] of the Gram–Schmidt orthonormalization
procedure [94]. The length of the projection of some other vector
in this subspace provides an estimate of vector-subspace
similarity.
For the double-predicate discovery patterns model, a drug’s
query subspace was constructed from this drug’s ﬁrst-degree
semantic vector bound to the vector representations of the ﬁve
double predicate reasoning pathways most frequently inferred
from other drugs. For the double- and triple-predicate discovery
patterns model, a drug’s query subspace also included this drug’s
second-degree semantic vector bound to vector representations
of the ﬁve reasoning pathways most frequently inferred from the
second-degree semantic vectors of other drugs.
The length of the projection of the semantic vector for a candi-
date ADR into a drug’s query subspace was used to estimate the
relatedness between these entities, providing a ranked list of
potential ADRs for each drug.
Fig. 4 provides an overview of the PSI-based analogical reason-
ing process in its entirety.3.3. Experimental design
An overview of the experimental design is shown in Fig. 5. The
ﬁrst experiment was conducted without knowledge of drug indica-
tions. The concept-based RRI model and discovery pattern-based
PSI model were compared with respect to their ability to identify
known drug/ADR associations. In the second experiment, the
model with the best performance from the ﬁrst experiment was
used to evaluate the effect of eliminating known indications from
the list of predictions.3.3.1. Experiment 1 design
Distributional semantic vectors were used to model MMB and
SemMedDB. RRI vectors and PSI vectors formed the basis for our
models of LBD concept-based co-occurrence and LBD discovery
patterns, respectively. As MetaMap may retrieve many more con-
cepts from a particular document than SemRep retrieves predica-
tions, we varied the RRI model to assess the extent to which
observed effects were due to the advantage of a more extensive
(albeit less structured) knowledge base. In one case, a RRI space
was derived from only those sentences from which predications
were extracted. Consequently, there are three distributional
semantic models – RRI built from documents (RRI-from-document
group), RRI built from predication source sentences (RRI-from-
predication group), and PSI built from predications. The PSI model
was evaluated with two settings. In the ﬁrst case, only two-predi-
cate discovery patterns were considered (PSI-double group), while
the second case considered both two- and three-predicate patterns
(PSI-double + triple group). The elemental vectors for terms, which
are not meaningfully related to one another, were used to imple-
ment a random baseline (Baseline group).
With the RRI models, for each drug, related problems were
sought by comparing each vector in the side effect search space
to this drug’s vector representation.
Fig. 3. The pseudo code for PSI model training process.
Fig. 2. Schematic representation of RRI training and inference process.
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used to infer predicate paths. For the PSI-double group, each drug’s
query subspace was built as the disjunction of the bound products
between the drug and its ﬁve double-predicate reasoning pathways.
For the PSI-double + triple group, each drug’s query subspaceadditionally included the second degree semantic vector of this drug
bound to ﬁve triple-predicate paths. The ﬁve triple-predicate paths
were retrieved by the extension of second degree semantic vectors
of drugs. Comparing a drug’s query subspacewith each vector in the
search space allowed us to infer the drug’s possible side effects.
Fig. 4. Schematic representation of PSI training and inference process. triglycerides: TG; myocardial infarction: MI; INTERACTS_WITH: IW; COEXISTS_WITH: CoeW;
ASSOCIATED_WITH: AW; COMPARED_WITH: ComW.
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From our preliminary results, we found that there were some
indications in the inferred ADRs. So we hypothesized that exclud-
ing known indications for drugs from the search space would
improve performance. We tested this hypothesis in the second
experiment utilizing knowledge of drug indications from MEDI.
In this experiment, we tested variants of the MEDI indication list
using the best performing model from the ﬁrst experiment (PSI
double + triple group). We extended the MEDI-complete and
MEDI-HPS lists to include all offspring, or immediate offspring
nodes based on the UMLS semantic network utilizing the
MRREL.RRF ﬁle. This ﬁle includes relationships between UMLS con-
cepts found in the UMLS Metathesaurus [95]. By utilizing these
ancestor-offspring hierarchical relationships, we deﬁne an off-
spring node as a node that has a MEDI indication as an ancestor
(regardless of the number of intervening nodes); and an immediate
offspring node as a node that has this MEDI indication as its parent.
In this procedure, we ﬁrst normalized all MEDI terms. For MEDI
drugs, we mapped each drug’s RxCUI to a UMLS CUI with theRxNorm API [96] and then subsequently searched the UMLS CUI
in SemMedDB and MMB to retrieve the mapped UMLS concept.
For MEDI indications, we mapped each indication’s ICD-9 term to
a UMLS CUI using the UTS API 2.0 [80] and then subsequently
searched for this UMLS CUI in SemMedDB and MMB to retrieve
the mapped UMLS concept. After normalizing MEDI terms, the
hierarchical relation of synonym (SY), child (CHD), and sibling
(SIB) in MRREL.RRF were used to ﬁnd drugs’ MEDI indications
extended offspring or immediate offspring. Consequently, there
were six MEDI lists (Table 1). These MEDI lists were used to
exclude indications from the side effect search space and were
tested in the second experiment.
3.3.3. Performance measurements
To evaluate performance, we used a number of widely used
metrics. Precision measures the proportion of accurate ADRs in
relation to the total number of ADRs retrieved [97]. To evaluate
the precision at different points in a ranked list, we used Average
Precision (AP, the average of the precision values measured at
Fig. 5. Experimental design in the detection of SIDER2 known ADRs using LBD
distributional semantic models.
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[98]). Mean average precision (MAP) is the average of the AP across
all drugs. Precision at k [98] measures the precision at ﬁxed levels
of retrieved results and emphasizes the importance of ﬁnding rel-
evant results early. We evaluated precision at k ¼ 50 (Pk=50). Recall
represents the proportion of ADRs retrieved out of the total num-
ber of ADR associations in the reference standard [97].
We deﬁne a ‘‘rediscovery’’ (true discovery) as an adverse effect
inferred by a vector model and subsequently conﬁrmed by SIDER2
as a true prediction. Consequently, the median rediscovery rank for
a particular drug approximates the point in the ranked list pro-
duced by a particular model at which half of the known adverse
reactions for this drug were recovered.
The AP and median rank of the rediscoveries across drugs were
compared by the paired t test and the Wilcoxon matched-pairs
signed-rank test, respectively.
To measure the performance with respect to the true positive
rate (TPR) and false positive rate (FPR), receiver operating charac-
teristic (ROC) curve was plotted for all drug/ADR pairs for all mod-
els. Subsequently, a global area under the ROC curve (AUC, ‘‘global’’
indicates that the scores of all drug-ADR pairs were combined into
a single curve) was calculated using AUCCalculator [99]. For the
model with the best global AUC, a drug-based AUC was also calcu-
lated and compared between drugs.4. Results
4.1. Experiment 1
4.1.1. Inferring discovery patterns
The most strongly associated double-predicate path was calcu-
lated for each known drug/ADR pair. In total, 90,787 predicateTable 1
Different groups by extending MEDI in experiment 2.
MEDI intervention Extension procedure
No MEDI None
MEDI-HPS indications for SIDER2 drugs All synonym (SY), child (CHD), and sib
Immediate synonym (SY), child (CHD)
MEDI-complete indications for SIDER2 drugs None
All synonym (SY), child (CHD), and sib
Immediate synonym (SY), child (CHD)paths were inferred. Among them, there were 1485 unique predi-
cate paths. The ﬁve most frequently inferred double-predicate
paths were selected. Second degree semantic vectors for drugs
were constructed by adding together the semantic vector repre-
sentations of any concept occurring in a semantic predication with
the drug in question, where the predicate type was either INTER-
ACTS_WITH or COMPARED_WITH. The most frequently occurring
double predicate paths and inferred triple predicate paths with
corresponding examples are shown in Table 2. They are consistent
across all drugs. Many of these paths are readily interpretable, and
could support a plausible biological mechanism for a predicted
effect. For example, INTERACTS_WITH:CAUSES-INV suggests a
drug may interfere with some biological factor which may cause
a side effect. COMPARED_WITH:CAUSES-INV can be used to iden-
tify similar side effects by comparing their drug class information
as COMPARED_WITH often indicates a comparative evaluation
across different drugs in the same therapeutic category. Triple
predicate paths extend the connecting path for drugs and related
ADRs.
4.1.2. Performance
Results for different vector models are shown in Table 3. PSI-
based models performed better than RRI-based models and both
models perform better than the random baseline. The PSI-dou-
ble + triple group outperformed all other groups. All differences
in median rank andMAP were statistically signiﬁcant (as estimated
by Wilcoxon’s signed rank test and paired t test respectively). Pk¼50
for each drug was compared across groups using Pearson’s correla-
tion. For variants of the same model (RRI or PSI), Pk¼50 was highly
correlated (0.75–0.84). Correlation in Pk¼50 between the PSI and
RRI models was between 0.52 and 0.57, suggesting the potential
to improve performance by combining results.
4.1.3. AUC
Fig. 6 and Table 3 present the global ROC curves for all models.
ROC curve shows the tradeoff between sensitivity and speciﬁcity.
The global AUC provides a cumulative estimate of accuracy, and
is shown for each model in Table 3. PSI-double + triple group has
the best global AUC of 0.6841. We measured its AUC at the drug
level (Fig. 7). The mean and median AUC are 0.7102 ± 0.0752 and
0.7058 respectively. Fig. 7 shows a plot of the AUC for each drug
against the log of the number of predications in SemMedDB with
this drug as subject. This suggests a trend in which performance
is generally better for those drugs for which more knowledge is
available in the database. Those drugs with an AUC of 0.8 or above
tend to occur in 10,000 or more predications as subject.
Note that the global AUC as a metric will be inﬂated by methods
that incorporate category bias into their prediction [100,101], a
subject we will return to in the discussion section.
4.1.4. Rediscovery results
The results of this experiment are illustrated in Fig. 8. This ﬁg-
ure plots the number of rediscovered side effects (left Y axis) and
the proportion of the valid side effects rediscovered (or globalExperiment group
No-MEDI group
ling (SIB), as well as their offspring MEDI-HPS-offspring group
, and sibling (SIB) relationships MEDI-HPS-immediate offspring group
MEDI-complete group
ling (SIB), as well as their offspring MEDI-complete-offspring group
, and sibling (SIB) relationships MEDI-complete-immediate offspring
group
Table 2




INTERACTS_WITH Dipyridamole INTERACTS_WITH nitric oxide
CAUSES-INV Bradycardia CAUSES-INV nitric oxide
ASSOCIATED_WITH Rosiglitazone COEXISTS_WITH apolipoprotein a-ii
COEXISTS_WITH Apolipoprotein a-ii ASSOCIATED_WITH myocardial
infarction
COMPARED_WITH Bisoprolol COMPARED_WITH metoprolol
CAUSES-INV Hypotension CAUSES-INV metoprolol
ASSOCIATED_WITH Rosiglitazone INTERACTS_WITH triglycerides
INTERACTS_WITH Triglycerides ASSOCIATED_WITH myocardial infarction
ISA Naproxen ISA calcineurin inhibitor
CAUSES-INV Toxic nephropathy CAUSES-INV calcineurin inhibitor
INTERACTS_WITH Rosiglitazone INTERACTS_WITH lyrm1
INTERACTS_WITH Lyrm1 INTERACTS_WITH fatty acids, nonesteriﬁed
ASSOCIATED_WITH Fatty acides, nonesteriﬁed ASSOCIATED_WITH
myocardial infarction
INTERACTS_WITH Rosiglitazone INTERACTS_WITH glycerol-3-phosphate
dehydrogenase
ASSOCIATED_WITH Glycerol-3-phosphate dehydrogenase COEXISTS_WITH
succinate dehydrogenase
COEXISTS_WITH Succinate dehydrogenase ASSOCIATED_WITH
myocardial infarction
COMPARED_WITH Rosiglitazone COMPARED_WITH glycerophosphates
INTERACTS_WITH Glycerophosphates INTERACTS_WITH low-density
lipoproteins
ASSOCIATED_WITH Low-density lipoproteins ASSOCIATED_WITH
myocardial infarction
COMPARED_WITH Rosiglitazone COMPARED_WITH gw 501516
COEXISTS_WITH Gw 501516 COEXISTS_WITH high-density lipoprotein
cholesterol
ASSOCIATED_WITH High-density lipoprotein cholesterol
ASSOCIATED_WITH myocardial infarction
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suggested potential ADRs (X axis) at different statistical thresholds.
All distributional models outperform the random baseline.
With approximately 100 predictions per drug, baseline, RRI-
from-predication, RRI-from-document, PSI-double and PSI-dou-
ble + triple group have a global recall of 0.029, 0.045, 0.069,
0.088, 0.125, respectively.4.2. Experiment 2
The PSI-double + triple model was the best performing model in
the ﬁrst experiment, and was selected to test the effects of using
variants of the MEDI list as a way to exclude therapeutic relation-
ships to reduce the number of highly ranked false positive
predictions.
Table 4 presents the performance of the PSI-double + triple
model when different MEDI lists were used. The median rank of
true positive predictions was lower when MEDI was used toTable 3
Results of precision and rank-based measures for different groups.





PSI-double + triple 0.0848 0.1410exclude the indication from the search space for each drug. How-
ever, as median rank is based on the rank of true positive results
only, it does not consider known side effects that may have been
excluded from consideration by the MEDI list. In contrast, MAP also
measures whether true side effects have been excluded. Conse-
quently, MAP in the MEDI-complete-immediate offspring was
higher than other groups. Overall, AUC was highest for the MEDI-
HPS-immediate offspring group. Of the models, only the MEDI-
HPS-immediate offspring group outperformed the baseline PSI
model by all metrics, and the improvements in performance were
small in comparison with the differences in performance between
distributional models in experiment 1. All differences between all
MEDI intervention groups and No-MEDI group in Pk¼50 are statisti-
cally signiﬁcant as measured by the paired t test. However, the
improvement in cumulative accuracy is negligible.4.3. Plausibility evidence found by PSI discovery patterns approach
In this paper, the association between rosiglitazone and myo-
cardial infarction, a highly publicized ADR discovered after the
drug was released to the market, is used to illustrate how evidence
from the literature can be retrieved for the evaluation of plausibil-
ity by a domain expert. The term ‘‘myocardial_infarction’’ was
ranked in the top 1% ðrank ¼ 29Þ and top 1.5% ðrank ¼ 50Þ of poten-
tial side effects for rosiglitazone by the PSI-double and PSI-dou-
ble + triple models respectively.
Rosiglitazone is a thiazolidinedione (TZD) antidiabetic drug,
used to treat type 2 diabetes mellitus as an adjunct to lifestyle
changes [102–104]. Since its approval by the FDA in 1999, rosiglit-
azone was prescribed 3.8 million times annually up to June 2009 in
the United States [105]. A meta-analysis of clinical trials conducted
by Nissen and Wolski [106] in 2007 suggested that the use of ros-
iglitazone was associated with a signiﬁcant increase in the risk of
myocardial infarction. This led to rosiglitazone’s withdrawal from
the European market in 2010 and a rosiglitazone black-box warn-
ing in the U.S. [105,107]. In 2013, the FDA lifted some prescription
restrictions in the U.S. market based on a reevaluation of the Ros-
iglitazone Evaluated for Cardiac Outcomes and Regulation of
Glycaemia in Diabetes (RECORD) trial (ClinicalTrials.gov Identiﬁer
NCT00379769) [108], but the European suspension is still in effect
at the time of this writing.
Rosiglitazone is a nuclear peroxisome proliferator-activated
receptor (PPAR-gamma) agonist. The mechanism through which
rosiglitazone causes cardiovascular events is unclear, but is
thought to be related to unfavorable effects on triglycerides, low-
density lipoprotein cholesterol (LDL-C) particle size and density,
and greater afﬁnity for PPAR-gamma than other TZD drugs [109–
112]. To evaluate the extent to which these hypotheses were con-
sistent with information utilized by the PSI-double + triple model,
we reconstructed the pathways of predicates and concepts that
were consistent with the inferred discovery patterns used to make
this prediction.
For myocardial infarction, each discovery pattern that was used









































Fig. 6. ROC plot of true positive rate and false positive rate for all groups.



















Fig. 7. Performance of AUC for all drugs by PSI-double + triple group.

























































Fig. 8. Rediscovery plot for experiment groups.
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myocardial infarction through the discovery pattern. The middle
terms retrieved were ranked based on their inverse document
frequency. Since the indexed SemMedDB predications contain the
source literature ID (PMID), we also retrieved related literature
evidence that supports the prediction.
Consequently 108,100 unique predication pathways were
retrieved through 8 unique predicate paths (Table 5) with distinct
middle terms that connect rosiglitazone with myocardial infarc-
tion. Table 6 shows some example predication pathways, that were
composed of two or three predications. There were around 17 sen-
tences providing evidence to support each predication on average.
We analyzed middle terms’ semantic groups [113] and list the
sample with distinct predicate paths connecting with different
semantic groups (Fig. 9).
There were 2618 distinct predication pathways about ‘‘triglyc-
erides’’, ‘‘LDL lipoprotein’’ and ‘‘PPAR-gamma’’ specifying 247
unique middle terms.
Drilling down, Fig. 10 shows the connecting concepts between
LDL-C and myocardial infarction that fall along the reasoning path-
ways employed by the PSI-double + triple model. In each reasoning
pathway, the middle terms were ranked using inverse document
frequency, to approximate the weighting used by the predictive
model. For each predication in these pathways, the source sen-
tences from the literature were retrieved. For example, the article
‘‘A comparison of lipid and glycemic effects of pioglitazone and
rosiglitazone in patients with type 2 diabetes and dyslipidemia’’
[143] explains that rosiglitazone increased triglycerides compared
with pioglitazone and has different effect on plasma lipids which
may contribute to heart disease. Fig. 10 shows the middle terms
retrieved to justify that rosiglitazone may cause myocardial infarc-
tion via LDL-C.
The capacity to retrieve and organize knowledge in this way
suggests a new paradigm for information retrieval in which infor-
mation supporting a hypothesis of interest is automatically aggre-
gated and organized at the conceptual level. However, as the
number of assertions in the literature far exceeds the number of
documents, further research is needed to develop methods through
which to prioritize these assertions, and present them in a manner
conducive to human consumption.5. Discussion
This study evaluates the ability of scalable LBD methods based
on distributional semantics to rank the plausibility of connections
between drugs and potential ADRs. We ﬁnd that both the RRI and
PSI models are able to retrieve known side effects of drugs, but PSI
performs this task better, as one would anticipate given the addi-
tional information beyond co-occurrence that it encodes. The PSI
model can further provide the reasoning pathways that were used
to link a drug to a predicted side effect. Consequently, relevant lit-
erature can be retrieved to support the predictions, and provided to
experts for review. However further research is needed to develop
approaches through which the assertions underlying the large
numbers of reasoning pathways utilized by the model can be pri-
oritized for expert review, as these are too numerous for exhaus-
tive manual review. Ultimately, we aim to provide domain
experts with essential evidence while preventing information
over-load. Even though it is not the best performing model, the
RRI model has the advantages of a simple training process and
the availability of more data to draw upon (as MetaMap has higher
recall for concepts than SemRep has for predications). Conversely,
the PSI model has the advantage of modeling plausibility, a capa-
bility with the potential to assist expert clinical review for pharma-
covigilance. In addition, the correlation analysis between groups
Table 4
PSI-double + triple model performance across all tests with different MEDI lists. Best results are in boldface. Performance exceeding the baseline (results obtained by the best PSI
model without MEDI) is marked with an asterisk (⁄).
Group MAP Pk¼50 for all drugs Median rank ðn ¼ 3;436Þ AUC
Median Mean
No-MEDI 0.0848 0.1410 808 1108.47 0.6841
MEDI-HPS 0.0849⁄ 0.1417⁄ 807⁄ 1107.60 0.6839
MEDI-HPS-offspring 0.0798 0.1283 765 1050.75⁄ 0.6813
MEDI-HPS-immediate offspring 0.0866⁄ 0.1444⁄ 795⁄ 1094.41⁄ 0.6850⁄
MEDI-complete 0.0839 0.1401 809 1108.06⁄ 0.6831
MEDI-complete-offspring 0.0673 0.0917 681⁄ 953.76⁄ 0.6737
MEDI-complete-immediate offspring 0.0889⁄ 0.1467⁄ 773⁄ 1068.72⁄ 0.6821
Table 5
Reasoning pathways used to retrieve evidence from the literature for the pair
rosiglitazone – myocardial infarction.
Predicate path
COMPARED_WITH : COEXISTS_WITH : ASSOCIATED_WITH
COMPARED_WITH : INTERACTS_WITH : ASSOCIATED_WITH
INTERACTS_WITH : COEXISTS_WITH : ASSOCIATED_WITH
INTERACTS_WITH : INTERACTS_WITH : ASSOCIATED_WITH
COEXISTS_WITH : ASSOCIATED_WITH
INTERACTS_WITH : ASSOCIATED_WITH
COMPARED_WITH : ASSOCIATED_WITH : COEXISTS_WITH
INTERACTS_WITH : ASSOCIATED_WITH : COEXISTS_WITH
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tially be combined to improve performance on this task.
For predicting ADRs, several statistical models and ML algo-
rithms have been evaluated against an edition of SIDER, or a subset
of this repository. In addition to methodological differences, these
approaches have leveraged different data sets and a variety of
knowledge bases as a basis for making predictions. In the section
that follows, we will provide a review of these approaches, and
the performance they have documented for the prediction of ADRs
in SIDER.
Pauwel’s et al. represented drugs using as features the presence
or absence of chemical substructure components described in
PubChem [144]. In addition to standard supervised ML approaches,
they applied canonical correlation analysis (CCA), including a
sparse variant that emphasizes a small number of informative
features for each training example. These methods were used to
predict SIDER side effects, with a reported global AUC of
0.8932 [145] on a set of 1350 ADR and 888 drugs, using ﬁvefold
cross-validation.
Subsequently, Liu et al. applied ﬁve supervised ML algorithms
to the same SIDER set. In addition to the PubChem-derived chem-
ical substructure features used by Pauwel’s et al., features wereTable 6
Some example predications for possible mechanism of rosiglitazone causing myocardial inf
Middle term ‘‘LDL cholesterol lipoprotein’’; 123 unique predication pathways;
 rosiglitazone INTERACTS_WITH apolipoproteins_b [114,115] INTERACTS_WITH ldl
 rosiglitazone INTERACTS_WITH paraoxonase_1 [117] INTERACTS_WITH ldl_choles
Middle term ‘‘triglyceride’’; 1515 unique predication pathways;
 rosiglitazone COEXISTS_WITH triglycerides [110] ASSOCIATED_WITH myocardial_i
 rosiglitazone INTERACTS_WITH triglycerides [125,126] ASSOCIATED_WITH myocar
 rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase [127] COEXI
Middle term ‘‘ppar_gamma’’; 992 unique predication pathways; for example:
 rosiglitazone COEXISTS_WITH ppar_gamma [129–132] ASSOCIATED_WITH myocar
 rosiglitazone INTERACTS_WITH ppar_gamma [134–138] ASSOCIATED_WITH myoc
 rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase [127] COEXI
 rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase INTERACTS_
 rosiglitazone INTERACTS_WITH resistin [141] INTERACTS_WITH ppar_gamma [142drawn from DrugBank [146] (drug targets, transporters, and
enzymes), KEGG [147] (pathway information) and SIDER itself
(drug indications and side effects). A classiﬁer was built for each
SIDER ADR, and the classiﬁers were then evaluated on 832 SIDER
drugs (for which DrugBank IDs could be found) using ﬁvefold
cross-validation. The support vector machine (SVM) algorithm per-
formed best with a global AUC of 0.9524 on the full SIDER dataset
[101]. The authors attribute much of the improvement in perfor-
mance by this and other metrics to the effects of incorporating
SIDER side effects as features, suggesting that certain side effects
have a tendency to co-occur in drug label data.
Other authors have reported performance on subsets of SIDER
using similar methods. For cardio-toxicity related ADRs in SIDER,
a median AUC of 0.771 using SVM for prediction has been reported
[148]. In this case, features were selected from information about
intended drug targets in DrugBank, and information about off-tar-
get effects from an expanded protein–protein interaction network
developed using gene ontology (GO) annotations. A SVM classiﬁer
was built for each evaluated ADR and cross-validated on SIDER.
With respect to performance, two of these studies, Pauwels
et al. [145] and Liu et al. [101] report a global AUC of close to 0.9
or higher with the best of their methods. Though our results are
not directly comparable as we made predictions on a per-drug
rather than a per-ADR basis, the difference between the global
AUC of these methods and that obtained with our approach seems
large. However this difference in global AUC is misleading. As
noted by Liu and colleagues in their paper, the imbalance between
positive and negative examples across ADRs and the way in which
the global AUC was calculated in this work leads to an apparent
inconsistency between it and the other evaluation metrics pre-
sented. For example, Pauwels and his colleagues display the AUC
across different ADRs in a series of box plots, which shows a med-
ian AUC for the best-performing method (by this metric) of slightly
above 0.6. Acknowledging this issue, Liu et al. also report precision
and recall for each evaluated method with, for example, precisionarction.
_cholesterol_lipoproteins [116] ASSOCIATED_WITH myocardial_infarction [110]
terol_lipoproteins [118] ASSOCIATED_WITH myocardial_infarction [119]
nfarction [120–124]
dial_infarction
STS_WITH triglycerides [128] ASSOCIATED_WITH myocardial_infarction
dial_infarction [133]
ardial_infarction
STS_WITH ppar_gamma [139] ASSOCIATED_WITH myocardial_infarction
WITH ppar_gamma [140] ASSOCIATED_WITH myocardial_infarction
] ASSOCIATED_WITH myocardial_infarction
Fig. 9. The predications retrieved by reasoning pathway for rosiglitazone causing myocardial infarction with specifying semantic groups for concepts.
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Notably, the AUC in this case was around 0.95.
This apparent inconsistency can be explained by the effect of
the prevalence of positive examples for each ADR on the predictionstrength. This is readily apparent for simple algorithms such as
Naive Bayes, where the prior probability of a given category is
incorporated into the estimate. However, it is also an issue for
more sophisticated algorithms such as SVM [100] particularly
Fig. 10. Middle terms that were retrieved by PSI discovery patterns involving LDL-C.
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for many of the ADR examples: Liu et al. report a positive to nega-
tive ratio of around 1:166 for 554 of the 1135 ADRs. So given the
same set of features, instances in these cases are likely to receive
a lower prediction score than those in balanced cases. When these
scores are aggregated across examples to generate a global AUC,
ML methods that incorporate the category bias will obtain an
inﬂated global AUC on account of this tendency to assign lower
scores to instances with few positive examples. However, as noted
by Liu et al. and demonstrated by the other reported metrics, this
AUC is not an accurate reﬂection of the ability of these models to
detect positive examples.
To simulate the effects of category bias on global AUC, we per-
formed a simple experiment in which we multiplied the similarity
scores produced by our model by the proportion of positive exam-
ples for each drug. This roughly approximates the effects of an
accurately estimated prior class probability during cross-validation
experiments. This resulted in an increase of our global AUC from
0.68 to 0.88. We do not present this result for the purpose ofcomparative evaluation, as our experiments are not directly com-
parable with prior ML work for other reasons we will subsequently
discuss. Rather, we present it as an illustration of the dispropor-
tionate inﬂuence of category bias on global AUC, which under-
scores the issues with this evaluation metric raised by Liu et al.
We trust it will also serve to dispel the misleading impression that
the predictive accuracy of our methods is vastly inferior to that
reported previously.
As our method does not consider the number of ADRs associ-
ated with a particular drug, the global AUC and median AUC
approximately agree with one another. Our median AUC (across
all drugs) of 0.7058, which falls somewhere in between that
reported by Pauwels et al. [145] (across all ADRs) and Huang
et al. [148] (across cardio-toxicity related ADRs only). On account
of the difference in denominator these results are not directly com-
parable, but they do further illustrate the discrepancy between glo-
bal and local AUC in models that are not agnostic to class
imbalance. Arguably such agnosticism is desirable from the per-
spective of an expert review, as it is difﬁcult to justify the assertion
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be considered less likely to cause some newly observed side effect
(and vice versa).
With respect to methodological differences, all of the above
methods are supervised ML methods, and were applied to infer
whether or not drugs were associated with each ADR from the fea-
tures of other drugs known to be associated with this ADR. So the
predictive models were generally customized on a per-ADR basis,
for example by generating an individual classiﬁer for each ADR in
the case of SVM. In contrast, our approach infers a set of abstract rea-
soning pathways that were consistent across the drugs we evalu-
ated. However, as illustrated by the absence of evidence across
certain pathways in the rosiglitazone example, some pathways
may be more predictive for particular medications or ADRs. So it
seems likely that we could further improve our performance by
incorporating supervisedML, adirectionweplan to explore in future
work.
Our approach differs with respect to the knowledge sources uti-
lized also. For example, KEGG and DrugBank are manually curated
databases. Our knowledge base, SemMedDB, contains predications
that have been automatically extracted by SemRep from the bio-
medical literature using NLP. Inaccuracies in language processing,
or indeed in the literature itself may introduce sources of error that
are not present in manually curated data. However, the scope of
the literature is much broader than that of human-curated
resources. Furthermore, as there is no agreed-upon gold standard
for ADRs, different studies have utilized different datasets as refer-
ence sets [149]. Our study employed SIDER2, which includes con-
siderably more drugs and ADRs than SIDER1.
This work has several limitations. The ﬁrst of these concerns the
use of SIDER2 as a reference standard. As SIDER2 consists of recog-
nized side effects only, we cannot reliably distinguish between
false positive signals and previously unknown ADRs. Furthermore,
SIDER was compiled from package insert information by NLP tools
[79], and as such may include side effects that seldom occur in
practice or false associations that were caused by text-mining
errors [150]. While SIDER2 is sufﬁcient to evaluate the hypotheses
of the current work, in future work we plan to incorporate other
data sources, such as EHR data and FDA reports. These data sources
may provide additional evidence to support the assertion that an
unknown drug/ADR pair is worth investigating further. Alterna-
tively, they may provide the means to select a subset of the side
effects in SIDER2 that have been observed frequently in practice
as an additional evaluation set.
Secondly, the MMB repository contains one year less literature
than the SemMedDB dataset. There is a difference of 1,7579,64 cita-
tions (7.9% of SemMedDB dataset). These were the newest datasets
at the time of the experiment. However the MMB repository has
many more data points than SemMedDB. For example, more than
99.99% of citations have concepts extracted by MetaMap and
59.91% of citations have predications extracted by SemRep.
Another concern is the existing knowledge about causal rela-
tionships between drugs and related ADRs from the literature.
For our dataset (90,787 pairs), 45% of pairs (concerning 953 drugs)
co-occur directly in the MMB repository and 5% of pairs (concern-
ing 693 drugs) have direct causal relationship (drug CAUSES ADR)
in SemMedDB. So PSI’s accuracy is dependent upon its ability to
meaningfully infer connections between concepts that were not
previously linked in its database, a capacity that would be particu-
larly useful as a means of assessing novel ADRs that had not previ-
ously been documented in the literature. RRI is also able to draw
such inferences, but in this case more of its performance may be
attributable to direct co-occurrence.
Inspecting the middle terms that our model retrieved for rosig-
litazone-MI association (Fig. 10), we found that at times uninfor-
mative high-level concepts, such as ‘‘genes’’ and ‘‘proteins’’, wereretrieved. In our study, we addressed the issue of uninformative
high level concepts in two ways, both related to their propensity
to occur relatively frequently in the corpus. Firstly we used a fre-
quency threshold of 1,000,000 to exclude frequently occurring con-
cepts contained in SemMedDB. The frequency of ‘‘genes’’ and
‘‘proteins’’ is less than the threshold and cannot be ﬁltered. Sec-
ondly, we used a weighting procedure to reduce the inﬂuence of
high-frequency terms on the training process. However, more
sophisticated approaches to ﬁltering are possible. Information con-
cerning UMLS semantic types and position in the UMLS hierarchy
could be used to develop more sophisticated approaches, to further
ﬁlter out uninformative high-level concepts, which may improve
performance.
The predictions made by PSI depend upon assertions extracted
from the biomedical literature. One concern about the extracted
predications is that they may be implausible on account of NLP
errors. Though SemRep has been optimized for precision, its preci-
sion is not perfect. For example, Kilicoglu et al. estimate the preci-
sion of SemRep to be around 0.77 [151]. Based on this, and other
published evaluations [152,69], it is reasonable to estimate that
around three in four predications in the set are perfectly accurate.
In many cases, inaccurate predications nonetheless indicate co-
occurrence, which is also informative. The PSI-based analogical rea-
soning approach we have employed is robust to isolated language
processing errors, as highly ranked predictions are based on asser-
tions extracted from thousands of unique reasoning pathways. For
example, for the rosiglitazone-MI association, 108,100 unique pred-
ications were retrieved, spanning eight of the inferred reasoning
pathways. On average, individual predications were supported by
17 excerpts from the literature. If we extrapolate from prior pub-
lished evaluations of SemRep, the predication concerned would
have been accurately extracted from around 12 of these excerpts.
So it is likely that at least some of the evidence supporting each indi-
vidual assertion is accurate. Moreover, as this method is distribu-
tional in nature, it does not require that these assertions be
perfectly accurate. Rather, the frequency with which an assertion
is extracted factors into the strength of its contribution to a reason-
ing pathway. Nonetheless, the biomedical literature may contain
controversial assertions, or contradictory conclusions fromdifferent
experts or different experiments. This is illustrated by the rosiglitaz-
one (brandname: Avandia) case. In 2007, the FDA added a black-box
warning for heart-related risks to Avandia based on ameta-analysis
[106] and three other studies [153]. In 2013, the FDA lifted certain
Avandia prescribing restrictions based on the readjudicated results
of the RECORD trial [154,155], claiming the initial concerns were
overblown [108]. This decision was condemned by one of the
authors of the original meta-analysis [156]. Currently our models
weight the contribution of assertions using statistics related to local
and global frequency. However, it would also be possible to weight
the importance of these assertions based on some assessment of
the reliability of the source. For example, in information retrieval
experiments, an approach incorporating citation information was
better able to identify articles considered as important in a pre-
existing bibliography [157]. Possibilities include weights derived
from the citation count of the source article, the impact factor of
the journal, or the nature of the experiment described. It is possible
thatweightingmetrics of this sourcewould improve the predictions
of our models, and they also suggest approaches to prioritize the
large numbers of assertions supporting our predictions for review
by human experts.6. Conclusion
In this research, an emerging, scalable method of LBD that uses
distributional statistics to infer and apply discovery patterns was
308 N. Shang et al. / Journal of Biomedical Informatics 52 (2014) 293–310adapted to evaluate the plausibility of drug/ADR relationships for
the purpose of pharmacovigilance. The effective application of
large amounts of partially accurate biomedical knowledge to this
problem was facilitated by the scalable and robust nature of
approximate inference in geometric space. This approach was
shown to be more effective than a comparable co-occurrence based
baseline, and has the further beneﬁt of permitting the retrieval of
evidence underlying the assertions used by the system to make
its predictions. Consequently, our approach provides the means
to assist with expert clinical review by providing evidence support-
ing the plausibility of the connection between drugs and ADRs.
Furthermore, the models we have developed can be applied to ﬁl-
ter drug/ADR signals that are detected in spontaneous reporting
systems or EHR data, a direction we plan to explore in future work.Acknowledgments
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